Journal article
Peptidomimetics Therapeutics for Retinal Disease
Biomolecules (Basel, Switzerland), Vol.11(3), p.339
02/24/2021
DOI: 10.3390/biom11030339
PMID: 33668179
Abstract
Ocular disorders originating in the retina can result in a partial or total loss of vision, making drug delivery to the retina of vital importance. However, effectively delivering drugs to the retina remains a challenge for ophthalmologists due to various anatomical and physicochemical barriers in the eye. This review introduces diverse administration routes and the accordant pharmacokinetic profiles of ocular drugs to aid in the development of safe and efficient drug delivery systems to the retina with a focus on peptidomimetics as a growing class of retinal drugs, which have great therapeutic potential and a high degree of specificity. We also discuss the pharmacokinetic profiles of small molecule drugs due to their structural similarity to small peptidomimetics. Lastly, various formulation strategies are suggested to overcome pharmacokinetic hurdles such as solubility, retention time, enzymatic degradation, tissue targeting, and membrane permeability. This knowledge can be used to help design ocular delivery platforms for peptidomimetics, not only for the treatment of various retinal diseases, but also for the selection of potential peptidomimetic drug targets.
Details
- Title: Subtitle
- Peptidomimetics Therapeutics for Retinal Disease
- Creators
- Dylan E Parsons - Stanford ChEM-H Medicinal Chemistry Knowledge Center, Stanford University, Palo Alto, CA 94305, USASoo Hyeon Lee - Molecular Surgery Laboratory, Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA 94304, USAYoung Joo Sun - Molecular Surgery Laboratory, Department of Ophthalmology, Byers Eye Institute, Stanford University, Palo Alto, CA 94304, USAGabriel Velez - Medical Scientist Training Program, University of Iowa, Iowa City, IA 52242, USAAlexander G Bassuk - Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USAMark Smith - Stanford ChEM-H Medicinal Chemistry Knowledge Center, Stanford University, Palo Alto, CA 94305, USAVinit B Mahajan - Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA
- Resource Type
- Journal article
- Publication Details
- Biomolecules (Basel, Switzerland), Vol.11(3), p.339
- DOI
- 10.3390/biom11030339
- PMID
- 33668179
- NLM abbreviation
- Biomolecules
- ISSN
- 2218-273X
- eISSN
- 2218-273X
- Publisher
- Switzerland
- Language
- English
- Date published
- 02/24/2021
- Academic Unit
- Neurology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Biochemistry and Molecular Biology; Neurology (Pediatrics)
- Record Identifier
- 9984070359002771
Metrics
17 Record Views